Posted by Michael Wonder on 10 Feb 2022
Biogen urges Medicare to reverse proposed limits on coverage of Alzheimer's drug
11 February 2022 - Biogen is urging Medicare to broadly reimburse its recently authorised Alzheimer's drug, in response to a proposal by the U.S. government to sharply limit coverage of new drugs for the brain-wasting disease.
